Krystal Biotech (NASDAQ:KRYS) Director Dino Rossi Sells 18,950 Shares

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Dino Rossi sold 18,950 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the sale, the director owned 78,691 shares of the company’s stock, valued at $20,570,614.31. The trade was a 19.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $274.59 on Tuesday. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $298.30. The stock has a fifty day moving average of $266.13 and a 200-day moving average of $211.66. The company has a market capitalization of $8.03 billion, a PE ratio of 40.09 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. As a group, research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on KRYS. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, February 18th. Zacks Research lowered shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Citigroup raised their price objective on shares of Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Bank of America lifted their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group increased their target price on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $318.75.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada raised its holdings in shares of Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares in the last quarter. AQR Capital Management LLC increased its position in Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Krystal Biotech by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Krystal Biotech during the 1st quarter worth about $218,000. Finally, CWM LLC lifted its holdings in shares of Krystal Biotech by 7.2% during the 2nd quarter. CWM LLC now owns 1,583 shares of the company’s stock valued at $218,000 after buying an additional 107 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.